Two Drug Makers Post Manufacturer Notices for 340B Overcharges

Manufacturer notices
Meitheal Pharmaceuticals and Purdue Pharma are each sending 340B covered entities refunds for overcharges totaling $100 or more.
Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HRSA Allows Immediate 340B Enrollment in Hawaii Due to Wildfires

Hawaii wildfires
HRSA is allowing eligible covered entities in Hawaii to enroll in the 340B program immediately rather than having to wait for the next quarterly registration period.
Eligible covered entities in Hawaii may enroll in the 340B program immediately rather than having to wait for the next [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Lobbying Activity Experiences Historic Surge

Capitol building
Key House Republicans on Tuesday introduced long-awaited—and contentious—legislation to overhaul the 340B program.
The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Program Does Not Improve Hospital Inpatient Care for Medically Underserved Patients, HHS-Funded Study Finds

Health Services Research study
A Health Services Research study with funding from a government agency suggested the 340B program does not improve hospital inpatient care quality.
The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GSK Giving 340B Entities Refunds Again for Asthma Medicine Purchases

GSK headquarters
Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.
GlaxoSmithKline is sending 340B covered entities refunds for overcharges totaling $100 or more for purchases of two dosage forms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Enforceability of State Contract Pharmacy Laws Uncertain Amid Legal Challenges

Louisiana capitol
PhRMA has asked a federal district judge to block Louisiana's 340B contract pharmacy law, Act 358, which took effect Aug. 1.
While two drug manufacturers have recently relaxed or suspended their 340B contract pharmacy restrictions as a result of state laws [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AHA Warns of “Legal Consequences” from Proposed Cuts to Fund 340B Lump Sum Payments

American Hospital Association logo
AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”
The lead plaintiff in the legal battle that resulted in Medicare proposing an unusual lump sum payback for hospitals’ lost [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Let For-Profit Hospitals Into 340B, Trade Association Tells Senators

Federation of American Hospitals logo
The Federation of American Hospitals has asked six U.S. senators to let for-profit hospitals join the 340B program.
Congress should let for-profit hospitals into the 340B drug pricing program as “a long overdue evolutionary step” that will advance [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Medicare DSH Changes Will Cut 340B Access, Draw Legal Challenge, Say Attorneys

CMS headquarters
CMS issued the final rule to implement a $9 billion lump sum payment to 340B hospitals for previous illegal cuts between 2018 and 2021.
Changes in the ways Medicare calculates hospitals’ shares of low-income patients that were finalized in a recent payment rule will [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis

The Moran Company logo
A Moran Company study, funded by PhRMA, found 340B hospitals charge an average of 500% above acquisition costs for 20 high-cost drugs.
Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live